Laddar...
YAP1 mediates resistance to MEK1/2 inhibition in neuroblastomas with hyperactivated RAS signalling
Relapsed neuroblastomas are enriched with activating mutations of the RAS-MAPK signaling pathway. The MEK1/2 inhibitor trametinib delays tumor growth but does not sustain regression in neuroblastoma preclinical models. Recent studies have implicated the Hippo pathway transcriptional coactivator prot...
Sparad:
| I publikationen: | Cancer Res |
|---|---|
| Huvudupphovsmän: | , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6911631/ https://ncbi.nlm.nih.gov/pubmed/31672841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-1415 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|